What’s Next in Immunotherapy? Drs. Kim Margolin and Przemyslaw Twardowski Discuss Cancer Research

Immunotherapy has changed how physicians treat melanoma and several other cancers by helping the immune system recognize and respond to malignant cells. As research progresses, investigators are examining new immune checkpoints, personalized cancer vaccines, cellular therapies, and combinations of treatments that may benefit patients who do not respond adequately to existing options. In this original June 2024 interview, Kim Margolin, MD, and Przemyslaw Twardowski, MD, discuss the future of immunotherapy, clinical trials, and the challenges of developing more effective and tolerable treatments.

Dr. Margolin, a medical oncologist specializing in melanoma and other skin cancers, has spent decades investigating immunotherapy and participating in clinical research. Dr. Twardowski specializes in genitourinary malignancies, including kidney cancer, where immunotherapy has also become an important treatment approach.

Their discussion connects the Institute’s history in cancer immunology with current questions involving tumor biology, treatment resistance, biomarkers, and access to investigational therapies. Although important developments have occurred since the original interview, many of the scientific challenges discussed by both physicians remain relevant.

What Is the Future of Cancer Immunotherapy?

Immunotherapy includes several types of treatment that work with the immune system to recognize or attack cancer. Immune checkpoint inhibitors are among the most established examples, with important applications in melanoma, kidney cancer, lung cancer, and other malignancies.

Researchers are investigating how to improve responses, overcome resistance, reduce adverse effects, and identify which patients are most likely to benefit from specific approaches. Some strategies involve combining established immunotherapies, while others introduce new immune targets, personalized vaccines, or cell-based treatments.

In the original 2024 interview, Dr. Margolin discussed research involving therapeutic cancer vaccines in the adjuvant setting, where treatment is given after surgery to reduce the likelihood of cancer returning.

“We have what looks to be an exciting patient vaccine in melanoma in the adjuvant setting,” Dr. Margolin explained.

New Immune Checkpoints and Treatment Combinations

Kim Margolin MD discussing immunotherapy combinations and cancer clinical trials at Saint John's Cancer Institute
Kim Margolin, MD, discusses developing immunotherapy approaches, including combinations of immune-based treatments.

Checkpoint inhibitors target biological signals that help regulate immune activity. By blocking certain inhibitory pathways, these medications can allow immune cells to mount a stronger response against cancer. Established checkpoint targets include PD-1, PD-L1, and CTLA-4.

Investigators are also studying additional immune checkpoints and signaling pathways. Some experimental combinations are intended to overcome resistance to existing therapy, while others seek to improve treatment effectiveness without causing unacceptable toxicity.

However, increasing immune activity can also increase the risk of inflammatory and autoimmune complications. The potential benefits of combination treatment must therefore be weighed against its risks, and investigational approaches require appropriate clinical evaluation.

Engineering Cytokines to Improve Immunotherapy

Cytokines are signaling proteins involved in communication between immune cells. Some cytokines can stimulate immune responses against cancer, but systemic treatment may also cause substantial adverse effects.

Researchers are exploring engineered cytokines and alternative delivery approaches to improve their therapeutic properties. Dr. Margolin described the scientific challenge in the original interview:

“Sometimes in order to get those cytokines to be safe or effective, or to use them regionally… You have to really engineer them. So, you have to put them together in weird forms that are not found in nature, in order to enhance their activity or to mitigate their toxicities, and all of that is sort of a work in progress.”

– Kim Margolin, MD

These approaches remain areas of active investigation. Their effectiveness and safety depend on the specific drug, disease, treatment combination, and results of clinical studies.

Personalized Cancer Vaccines

Therapeutic cancer vaccines are designed to stimulate immune responses against tumor-associated targets. Unlike vaccines intended to prevent infectious diseases, these treatments generally aim to help the immune system recognize cancer cells in a person who has already been diagnosed.

Some experimental vaccines are individualized using molecular information obtained from a patient’s tumor. Researchers identify mutations that may produce abnormal proteins, known as neoantigens, and develop a treatment intended to direct immune responses toward those targets.

After Dr. Margolin’s 2024 interview, additional clinical trial results were reported involving individualized mRNA-based melanoma treatment. In August 2026, Merck and Moderna announced that a Phase 3 study of intismeran autogene combined with pembrolizumab met its primary recurrence-free survival endpoint and a distant metastasis-free survival endpoint in patients with resected melanoma.

These results were announced by the manufacturers and require interpretation alongside the full study data, regulatory review, and subsequent clinical guidance. The announcement should not be interpreted as FDA approval of the vaccine.

The development illustrates the continuing relevance of the vaccine research Dr. Margolin discussed in 2024.

Cellular Immunotherapy for Advanced Melanoma

Another immunotherapy approach involves collecting immune cells associated with a patient’s tumor, expanding them under controlled conditions, and administering them as treatment. One example is tumor-infiltrating lymphocyte (TIL) therapy.

In February 2024, the U.S. Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi), a TIL therapy, for selected adults with unresectable or metastatic melanoma following specified prior treatments.

This development represented an important milestone in cellular immunotherapy for solid tumors. However, the treatment is appropriate only for certain patients and involves a complex treatment process, including preparative therapy and monitoring for potentially serious adverse effects.

Learn more about Immunotherapy for Melanoma at Saint John’s Cancer Institute.

The History of Immunotherapy at Saint John’s Cancer Institute

Immunotherapy research has deep roots at Saint John’s Cancer Institute and its predecessor, the John Wayne Cancer Institute. Donald L. Morton, MD, contributed to melanoma research through investigations involving tumor immunology, cancer vaccines, and surgical treatment strategies.

One important milestone in the broader development of cancer immunotherapy was the approval of high-dose interleukin-2, also called aldesleukin. The FDA approved aldesleukin for metastatic renal cell carcinoma in 1992 and metastatic melanoma in 1998. Although it could produce durable responses in some patients, high-dose interleukin-2 was associated with potentially severe toxicity.

Later advances in immune checkpoint biology helped lead to treatments targeting CTLA-4 and PD-1. These therapies transformed the treatment landscape for advanced melanoma and subsequently became important in several other malignancies.

The Institute’s earlier vaccine and immune-response research provides historical context for today’s clinical investigations, including therapeutic cancer vaccines and new immunotherapy combinations.

Donald L. Morton’s Contributions to Melanoma Research

Dr. Morton’s work combined clinical investigation with laboratory research into cancer immunity. The Institute’s history includes studies involving melanoma vaccines, immune responses, and multicenter clinical trials.

Lisa van Kreuningen, Administrative Director of Saint John’s Cancer Institute at the time of the original article, described his research:

“He was pursuing it in parallel with his MSLT-I and II surgical trials, with a different NIH-funded program project grant. Dr. Morton developed a cancer vaccine and had many phase I/II clinical trials at the cancer center, followed by international, multicenter trials for both Stage III and State IV melanoma…he was ahead of his time,” explains Lisa van Kreuningen, Administrative Director of Saint John’s Cancer Institute.

Her account reflects the Institute’s history of investigating cancer vaccines and conducting clinical research alongside surgical oncology studies.

From Early Immunotherapy to Current Clinical Research

The development of checkpoint inhibitors, targeted therapies, and newer cellular approaches has expanded options for selected patients with melanoma. At the same time, researchers continue to investigate why some tumors respond well while others resist or eventually stop responding to treatment.

These questions remain central to translational research, which connects discoveries about tumor biology with clinical studies intended to evaluate new treatment approaches.

Watch Drs. Margolin and Twardowski Discuss Immunotherapy

In this original June 2024 interview, Drs. Margolin and Twardowski discuss melanoma, renal cell carcinoma, immune-based therapies, and research approaches under investigation at Saint John’s Cancer Institute.

The interview also examines the importance of clinical trials and the potential for different treatment approaches to benefit patients according to their individual cancer diagnoses and medical circumstances.

“At Saint John’s, we are doing several interesting trials.”

– Przemyslaw Twardowski, MD

Medical Oncologists Discuss the Future of Immunotherapy and Cancer Clinical Trials

Kim Margolin, MD, and Przemyslaw Twardowski, MD, discuss immunotherapy research and clinical trials at Saint John’s Cancer Institute. Original interview published June 2024.

How Does Personalized Medicine Influence Immunotherapy?

Personalized medicine seeks to use information about a patient’s cancer and clinical circumstances to guide treatment decisions. Molecular testing, tumor characteristics, prior treatment responses, and individual health factors can all influence which therapies may be appropriate.

In melanoma, molecular testing may identify alterations such as BRAF mutations that are relevant to targeted therapy. Immunotherapy selection also involves consideration of disease stage, previous treatment, potential adverse effects, and available evidence.

However, personalized medicine does not necessarily mean that a newly developed or molecularly selected treatment will outperform an established standard of care. The effectiveness of a particular strategy must be demonstrated in the relevant patient population.

Patient Experiences With Melanoma and Kidney Cancer

Saint John’s Cancer Institute has documented individual patient experiences involving immunotherapy and other treatments. These stories illustrate the importance of individualized care while recognizing that responses to treatment differ among patients.

Mike Antonson, a retired Air Force sergeant diagnosed with metastatic melanoma, has shared his experience receiving treatment under Dr. Margolin, including immune-based and targeted treatment approaches. His story documents the medical decisions and personal challenges associated with stage IV melanoma.

Read Dr. Kim Margolin, Her Patient With Stage IV Melanoma, and the Art of Medicine.

Andy Luci was diagnosed with metastatic renal cell carcinoma and received care from Dr. Twardowski involving immunotherapy. His experience provides another perspective on how immune-based treatments may be used for cancers outside the melanoma program.

Read A Husband and Wife Discuss Their Stage IV Renal Cell Carcinoma Journey.

These are individual patient experiences and do not establish that the same treatments will produce equivalent outcomes in other patients.

Biomarkers and Treatment Selection

Biomarkers are measurable biological characteristics that may provide information about a cancer or its response to treatment. Depending on the disease, they can help identify treatment targets, estimate certain risks, or support decisions about therapies.

Examples relevant to cancer immunotherapy include PD-L1 expression, tumor mutational burden, and other molecular or immune-related characteristics. Their usefulness varies among cancer types, and no single biomarker reliably predicts immunotherapy response for every patient.

Research continues to examine combinations of tumor, immune, and clinical information that may improve predictions of treatment benefit or resistance.

Clinical Trials, Expanded Access, and Right to Try

Clinical trials investigate the safety and effectiveness of treatments and may be available at different stages of cancer care. Some studies enroll patients who have already received several therapies, while others evaluate new approaches before surgery, after surgery, or alongside established treatment.

Participation is voluntary and requires eligibility assessment and informed consent. An investigational treatment may provide benefit, but that benefit is not guaranteed, and participation may involve additional risks or procedures.

Current research opportunities can be reviewed through the Saint John’s Cancer Institute Active Clinical Trials Directory.

Considering a Clinical Trial

A clinical trial does not necessarily have to be considered only after all standard treatments have been exhausted. Appropriate timing depends on the study’s purpose, eligibility requirements, the patient’s diagnosis, and the available treatment alternatives.

Patients should ask their physicians about potential benefits, risks, treatment alternatives, costs, and additional appointments before deciding whether a study is appropriate.

For an introduction to the research process, read International Clinical Trials Day: Hear From Experts in Oncology Research.

Expanded Access and Compassionate Use

Some patients with serious or immediately life-threatening conditions cannot participate in a clinical trial and have no comparable or satisfactory approved treatment available. Under certain circumstances, expanded access, sometimes called compassionate use, may permit access to an investigational medical product outside a clinical trial.

Expanded access involves regulatory requirements, physician participation, and cooperation from the manufacturer. It does not guarantee that the investigational treatment will be available or effective.

Dr. Margolin discussed these situations in the original interview:

“There are times when a patient really wants to try a drug and they heard of it already…You don’t have an ordinary trial for them that would consist of multiple institutes participating…The FDA calls it ‘expanded access,’ or compassionate use protocols for individual patients…, a ‘right to try.’”

– Kim Margolin, MD

For clarity, FDA expanded access and the federal Right to Try pathway are distinct mechanisms with different legal and procedural requirements. Right to Try applies to certain eligible patients and investigational drugs, while expanded access operates through FDA-regulated processes.

Patients interested in either pathway should discuss their situation with their treating oncologist and consult current FDA information.

Access to Treatment and Supportive Services

Access to immunotherapy can involve medical eligibility, insurance coverage, treatment location, clinical trial requirements, and potential out-of-pocket expenses.

Research participation may introduce additional logistical considerations, including testing, travel, scheduling, and communication among care teams. Patients and caregivers may benefit from discussing available financial counseling, navigation, or supportive services with their healthcare organization.

Can Artificial Intelligence Help Predict Immunotherapy Response?

Artificial intelligence and machine learning are being studied as tools to analyze clinical and molecular information that may be associated with treatment response. Researchers hope these methods will eventually help clinicians better identify patients who are likely to benefit from particular therapies.

In June 2024, researchers at the National Institutes of Health reported a proof-of-concept AI model that used clinical and biological information to estimate responses to immune checkpoint inhibitors across several cancer types. The research included features such as age, cancer type, previous treatment, blood test results, and tumor mutational burden.

The investigators emphasized that prospective studies were needed before the model could be adopted for routine clinical use. A prediction generated from an experimental algorithm does not replace a validated diagnostic test or individualized medical decision-making.

Dr. Margolin’s Perspective on Melanoma Biomarkers

In response to the 2024 NIH research, Dr. Margolin highlighted a limitation of applying findings from multiple tumor types directly to melanoma:

“Factors that may be useful in other tumors, particularly the tumor mutation burden and PD-L1 expression, don’t show enough variation in melanoma to act as discriminators for benefit from immunotherapy and we need deeper understanding of the mechanisms of action of each immunotherapy agent and of each type of melanoma before we can develop AI as a tool for predicting benefit,” disclosed Dr. Margolin.

Her comments illustrate why the development of predictive tools requires cancer-specific evidence. Biomarkers or algorithms that perform well in one disease may not provide the same information in another.

Although AI research has continued since the original interview, any clinical use must be supported by appropriate validation, evidence of benefit, and medical oversight.

Read the National Cancer Institute’s June 2024 report on AI and immunotherapy response.

Understanding Immune Checkpoint Terminology

Immune checkpoints are biological mechanisms that help regulate immune activity and prevent excessive immune responses. Some cancers exploit these pathways to limit the ability of immune cells to recognize and attack malignant cells.

Checkpoint inhibitors interfere with particular inhibitory signals. They can produce meaningful treatment responses in selected patients, but may also cause immune-related adverse effects affecting the skin, digestive tract, lungs, liver, endocrine organs, or other tissues.

PD-1

Programmed cell death protein 1 (PD-1) is a receptor expressed on certain immune cells, including activated T cells. When PD-1 interacts with its ligands, it can reduce immune activity.

Medicines that block PD-1, including pembrolizumab and nivolumab, have become important treatments for several cancers, including melanoma. Both received initial FDA approvals for advanced melanoma in 2014.

PD-L1

Programmed death-ligand 1 (PD-L1) is a protein found on some cancer cells, immune cells, and normal tissues. Its interaction with PD-1 can inhibit certain T-cell responses.

Anti-PD-L1 therapies block this interaction, although approved indications differ among drugs and cancer types. PD-L1 expression does not reliably determine immunotherapy benefit in every malignancy.

CTLA-4

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is another receptor involved in regulating T-cell activation. Ipilimumab blocks CTLA-4 and is used in selected melanoma treatment regimens, including certain combinations with anti-PD-1 therapy.

Because combinations can increase immune-related toxicities, treatment selection requires careful consideration of potential benefits, risks, and individual patient circumstances.

Cytokines and Cellular Therapy

Cytokines are immune signaling proteins that can affect the behavior of immune cells. Engineered cytokines are being studied to improve antitumor activity while reducing potentially serious adverse effects.

Cellular immunotherapies, including tumor-infiltrating lymphocyte therapy, involve collecting and preparing immune cells for treatment. Their use requires specialized clinical processes and is appropriate only in selected settings.

Continuing Immunotherapy Research at Saint John’s Cancer Institute

The Institute’s melanoma and genitourinary oncology programs participate in clinical research involving immune-based treatments and other therapeutic approaches. Drs. Margolin and Twardowski have contributed to this work through their respective areas of clinical expertise.

Research priorities continue to include improving treatment response, understanding resistance, evaluating new drug combinations, and identifying clinical or molecular characteristics that can guide patient selection.

As Dr. Twardowski observed in the original interview, “There’s still so much we don’t know.”

That uncertainty is an important reason clinical studies remain necessary. Promising laboratory findings and early clinical results must be evaluated through appropriately designed research before new therapies can be considered established treatments.

Readers can explore the Institute’s Active Clinical Trials and its Melanoma Immunotherapy Treatment Program. Those pages provide more current clinical context than the original 2024 interview.

The Future of Immunotherapy and Personalized Cancer Care

Immunotherapy continues to evolve through research involving checkpoint inhibitors, engineered cytokines, individualized cancer vaccines, cellular therapies, and biomarkers. The original discussion with Kim Margolin, MD, and Przemyslaw Twardowski, MD, captures important scientific questions about how these approaches may be developed and used for patients with melanoma and other cancers. Subsequent developments, including advances in personalized melanoma vaccines, demonstrate why ongoing research and careful evaluation remain essential.

Learn about Immunotherapy for Melanoma at Saint John’s Cancer Institute, explore the Borstein Family Foundation Melanoma Program, or review Active Clinical Trials for current research opportunities. Patients should discuss treatment options, eligibility, potential benefits, and risks with their medical oncology team.

Sources & Further Reading

About the Author

Eleanor Zeri

Eleanor Zeri contributes to the publication and editorial management of Saint John's Cancer Institute's blog, covering cancer research, patient experiences, clinical advances, and community health.